Intravenous (IV) acetaminophen is recognized for its strong antipyretic and moderate analgesic properties, with minimal anti-inflammatory effects. Compared to its oral counterpart, the IV formulation offers a more potent analgesic action, quicker onset, and significantly higher plasma concentrations. Additionally, it poses a lower risk of liver toxicity due to the bypassing of hepatic first-pass metabolism. Clinical evidence indicates a 46% reduction in opioid consumption on the first day following hip and knee surgeries, accompanied by decreased postoperative nausea and vomiting (PONV). However, it is crucial to monitor dosing to avoid liver toxicity; the recommended IV dosage should not surpass 15 mg/kg every 6 hours, with a daily ceiling of 4 grams. In patients with liver disease, the maximum daily dose should be confined to 2 grams.
Research, including systematic reviews and clinical trials, has consistently shown that IV acetaminophen can reduce postoperative opioid requirements by up to 30% within the first 4 hours post-operation. Despite this, the necessity of choosing IV over oral acetaminophen for patients capable of oral intake remains debated, especially when considering cost-efficiency. The impact of reduced opioid dosing on mitigating opioid-related side effects or adverse events remains unclear, with mixed findings across studies. Recent investigations, such as a study on spine surgery patients, suggest that IV acetaminophen may not significantly impact the inpatient use of opioids or opioid-related adverse events, indicating that its effectiveness could vary based on the surgical procedure and patient-specific factors. Further research is necessary to definitively ascertain IV acetaminophen's role in lessening opioid-related adverse events.
